Bactevo's core internal therapy area is mitochondrial disease. Mitochondrial diseases have a huge impact on patients’ lives and those of family members who have to care for them. They tend to be progressive with high degrees of
morbidity and mortality. Defined groups such as MELAS, LHON or Leigh syndrome are massively debilitating and include rapid vision and hearing loss, stroke-like episodes and other symptoms including fatigue which result in inability to conduct daily tasks without help or work.
Treatment is usually symptomatic, trying to relieve symptoms and can rapidly become expensive to the NHS as treatment is chronic, with repeated hospital stays due to episodic events. Although classed as rare, mitochondrial diseases affect at least 1 in 4000 people, or greater than 14,000 in the UK. Treating these patients costs the NHS directly over £260million/year and a recent pilot study by the UK government has estimated the net societal benefit to the UK of preventing mitochondrial disease is £22 billion/year.
The fundamental contribution of correct mitochondrial function to central nervous system diseases is becoming clear with some forms of early onset Parkinson’s disease (PD) caused by an inability to remove dysfunctional mitochondria and Alzheimer’s disease (AD) influenced by reduced mitochondrial function. Therefore, finding therapeutic medicines that can improve mitochondrial biogenesis and/or correct the biochemical defect will have a massive impact on human health for both orphan diseases as well as the general population suffering with currently untreatable diseases (AD), which threaten the viability of our modern health systems.
Bactevo have a collaboration with Professor Sir Doug Turnbull and Professor Robert Lightowlers at the Wellcome Trust Centre for Mitochondrial Research (WTCMR), which over the last 25 years has become the world leading centre for mitochondrial disease research, combining patient care with basic research.
Additional to the mitochondrial therapy area focus, Bactevo has been awarded an Innovate UK Biomedical Catalyst grant to pursue the discovery of novel antibiotics against highly resistant Gram-negative pathogens.